Effects and mechanism of CD4+ CD25+ regulatory T cells in mouse experimental colitis treated by CLYSTER No. 1.
- Author:
Xiao-xia AN
1
;
Yu-fang CUI
;
Ping LIU
;
Yan LI
;
Bo DONG
;
Shu-hua SUN
;
Xu-ni SHEN
;
Xiao-lan LIU
;
Jian-ping MAO
Author Information
- Publication Type:Journal Article
- MeSH: Animals; CD4 Antigens; immunology; Colitis; immunology; Disease Models, Animal; Drugs, Chinese Herbal; pharmacology; Female; Flow Cytometry; Interleukin-2 Receptor alpha Subunit; immunology; Male; Mice; Random Allocation; T-Lymphocytes, Regulatory; drug effects; immunology
- From: China Journal of Chinese Materia Medica 2008;33(14):1736-1738
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the effects and mechanism of CD4+ CD25+ regulatory T cells (Tregs) in mouse experimental colitis treated by CLYSTER No. 1.
METHODThe mouse model of experimental colitis was established by dinitrochlorobenzene (DNCB)-acetic acid (AA) in mice DNCB and AA. Adult KM mouse were randomly divided into four groups: normal control group, experimental colitis model group, SASP and Chinese medicine therapeutic groups. Proportion of CD4 CD25+ Tregs in peripheral blood (PB) and mesenteric lymph node (MLN) was estimated by flow cytometry at the end of one or two week after treating with SASP and CLYSTER No. 1.
RESULTThe model of experimental colitis in mouse was successfully established. Compared with normal control group, the proportion of CD4 CD25 Tregs was markedly decreased in PB and MLN of model control group of experimental colitis. But it was significantly increased in therapeutic groups of SASP and CLYSTER No. 1, and their CD4+ CD25+ Tregs in PB and MLN were much more than the model control group at the end of one or two weeks after treating with SASP and CLYSTER No. 1.
CONCLUSIONCD4+ CD25+ Tregs with strong immune suppression could play a central role in the initiation and development of mouse experiment colitis, and the CLYSTER No. 1 might exert its therapeutic effects on UC by the regulation of number and function of CD4+ CD25+ Tregs.
